Recall: Hospira infusion pump touchscreen issue gets Class I status from FDA

Mon, 10/29/2012 - 2:08pm
Mass Device

The FDA gives Hospira's infusion pump recall Class I status over touchscreen issues that may result in delayed or inaccurate medication delivery that could injure patients.

Hospira logo

Infusion pump maker Hospira (NYSE:HSP) recalled 2 of its touchscreen-enabled infusion pumps over software concerns that may affect medication delivery.

Hospira pulled all lots of its 16026 Symbiq One Channel Infusers and 16027 Symbiq Two Channel Infusers distributed at any time, warning that "the Symbiq pump touchscreen may not respond to user selection, may experience a delayed response or may register a different value from the value selected by the user," according to the FDA notice.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.